1
|
Zuo Y, Long Z, Li R, Le Y, Zhang S, He H, Yan L. Design, synthesis and antitumor activity of 4-arylamine substituted pyrimidine derivatives as noncovalent EGFR inhibitors overcoming C797S mutation. Eur J Med Chem 2024; 265:116106. [PMID: 38169271 DOI: 10.1016/j.ejmech.2023.116106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2023] [Revised: 12/26/2023] [Accepted: 12/26/2023] [Indexed: 01/05/2024]
Abstract
Clinical researches have shown that epidermal growth factor receptor (EGFR) is a key target for treatment of non-small cell lung cancer (NSCLC). Many EGFR inhibitors were successfully developed as ani-tumor drugs to treat NSCLC patients. Unfortunately, drug resistances were found in clinic. To overcome C797S mutation in EGFR, a novel series of 4-arylamine substituted pyrimidine derivatives were designed and synthesized under the principle of structure-based drug design. Interestingly, compounds 6e and 9i demonstrated the best anti-proliferative activity against A549, NCI-H1975, and HCC827 cells. In particular, the IC50 values against HCC827 cells reached to 24.6 nM and 31.6 nM, which were much lower than human normal cells 2BS and LO2. Furthermore, compounds 6e and 9i showed extraordinary activity against EGFR19del/T790M/C797S (IC50 = 16.06 nM and 37.95 nM) and EGFRL858R/T790M/C797S (IC50 = 11.81 nM and 26.68 nM), which were potent than Osimertinib (IC50 = 52.28 nM and 157.60 nM). Further studies have shown that compounds 6e and 9i could pertain inhibition of HCC827 colony formation, and arrest HCC827 cells at G2/M phase. Moreover, the most promising compound 6e could inhibit the migration of HCC827 cells, induce HCC827 cells apoptosis, and significantly inhibit the phosphorylation of EGFR, AKT and Erk1/2. In vivo xenograft mouse model with HCC827 cells, compound 6e resulted in remarkable tumor regression without obvious toxicity. In addition, molecular docking studies suggested that compound 6e could firmly combine with T790M-mutant, T790 M/C797S-mutant, and L858R/T790 M/C797S-mutant EGFR kinases as ATP-competitive inhibitor.
Collapse
Affiliation(s)
- Yaqing Zuo
- School of Pharmaceutical Sciences, Guizhou University, Guiyang, 550025, China
| | - Zhiwu Long
- School of Pharmaceutical Sciences, Guizhou University, Guiyang, 550025, China
| | - Rongrong Li
- School of Pharmaceutical Sciences, Guizhou University, Guiyang, 550025, China
| | - Yi Le
- School of Pharmaceutical Sciences, Guizhou University, Guiyang, 550025, China; State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China
| | - Silong Zhang
- School of Pharmaceutical Sciences, Guizhou University, Guiyang, 550025, China
| | - Huan He
- School of Pharmaceutical Sciences, Guizhou University, Guiyang, 550025, China
| | - Longjia Yan
- School of Pharmaceutical Sciences, Guizhou University, Guiyang, 550025, China; State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China.
| |
Collapse
|
2
|
Xiang J, Wang Y, Wang W, Yu J, Zheng L, Hong Y, Shi L, Zhang C, Chen N, Xu J, Gong X, Zhang Z, Cui H, Zhou Q, Zhang D, Liu Y, Ke Y, Shen J, Xia G, Bai X. Design, synthesis, and pharmacological evaluation of quinazoline derivatives as novel and potent pan-JAK inhibitors. Bioorg Chem 2023; 140:106765. [PMID: 37582330 DOI: 10.1016/j.bioorg.2023.106765] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2023] [Revised: 07/25/2023] [Accepted: 08/02/2023] [Indexed: 08/17/2023]
Abstract
Janus kinases (JAKs) play a critical role in modulating the function and expression of inflammatory cytokines related to rheumatoid arthritis (RA). Herein, we report the design, synthesis, and structure-activity relationships (SARs) of a series of novel quinazoline derivatives as JAK inhibitors. Among these inhibitors, compound 11n showed high potency against JAKs (JAK1/JAK2/JAK3/TYK2, IC50 = 0.40, 0.83, 2.10, 1.95 nM), desirable metabolic characters, and excellent pharmacokinetic properties. In collagen-induced arthritis (CIA) models, compound 11n exhibited significant reduction in joint swelling with good safety, which could be served as a potential therapeutic candidate for the treatment of inflammatory diseases.
Collapse
Affiliation(s)
- Jinbao Xiang
- The Center for Combinatorial Chemistry and Drug Discovery of Jilin University, The School of Pharmaceutical Sciences, Jilin University, Changchun, Jilin 130021, PR China
| | - Yuji Wang
- Central Research Institute, National Key Laboratory of Innovative Immunotherapy, Shanghai Pharmaceuticals Holding Co., Ltd., Shanghai 201203, PR China
| | - Wanhe Wang
- The Center for Combinatorial Chemistry and Drug Discovery of Jilin University, The School of Pharmaceutical Sciences, Jilin University, Changchun, Jilin 130021, PR China
| | - Jianxin Yu
- Central Research Institute, National Key Laboratory of Innovative Immunotherapy, Shanghai Pharmaceuticals Holding Co., Ltd., Shanghai 201203, PR China
| | - Lianyou Zheng
- The Center for Combinatorial Chemistry and Drug Discovery of Jilin University, The School of Pharmaceutical Sciences, Jilin University, Changchun, Jilin 130021, PR China
| | - Yuan Hong
- Central Research Institute, National Key Laboratory of Innovative Immunotherapy, Shanghai Pharmaceuticals Holding Co., Ltd., Shanghai 201203, PR China
| | - Lingling Shi
- The Center for Combinatorial Chemistry and Drug Discovery of Jilin University, The School of Pharmaceutical Sciences, Jilin University, Changchun, Jilin 130021, PR China
| | - Chunling Zhang
- The Center for Combinatorial Chemistry and Drug Discovery of Jilin University, The School of Pharmaceutical Sciences, Jilin University, Changchun, Jilin 130021, PR China
| | - Na Chen
- Central Research Institute, National Key Laboratory of Innovative Immunotherapy, Shanghai Pharmaceuticals Holding Co., Ltd., Shanghai 201203, PR China
| | - Jia Xu
- Central Research Institute, National Key Laboratory of Innovative Immunotherapy, Shanghai Pharmaceuticals Holding Co., Ltd., Shanghai 201203, PR China
| | - Xuelian Gong
- Central Research Institute, National Key Laboratory of Innovative Immunotherapy, Shanghai Pharmaceuticals Holding Co., Ltd., Shanghai 201203, PR China
| | - Zhuoqi Zhang
- The Center for Combinatorial Chemistry and Drug Discovery of Jilin University, The School of Pharmaceutical Sciences, Jilin University, Changchun, Jilin 130021, PR China
| | - Hongming Cui
- The Center for Combinatorial Chemistry and Drug Discovery of Jilin University, The School of Pharmaceutical Sciences, Jilin University, Changchun, Jilin 130021, PR China
| | - Qian Zhou
- The Center for Combinatorial Chemistry and Drug Discovery of Jilin University, The School of Pharmaceutical Sciences, Jilin University, Changchun, Jilin 130021, PR China
| | - Dapeng Zhang
- The Center for Combinatorial Chemistry and Drug Discovery of Jilin University, The School of Pharmaceutical Sciences, Jilin University, Changchun, Jilin 130021, PR China
| | - Yanjun Liu
- Central Research Institute, National Key Laboratory of Innovative Immunotherapy, Shanghai Pharmaceuticals Holding Co., Ltd., Shanghai 201203, PR China
| | - Ying Ke
- Central Research Institute, National Key Laboratory of Innovative Immunotherapy, Shanghai Pharmaceuticals Holding Co., Ltd., Shanghai 201203, PR China
| | - Jingkang Shen
- Central Research Institute, National Key Laboratory of Innovative Immunotherapy, Shanghai Pharmaceuticals Holding Co., Ltd., Shanghai 201203, PR China
| | - Guangxin Xia
- Central Research Institute, National Key Laboratory of Innovative Immunotherapy, Shanghai Pharmaceuticals Holding Co., Ltd., Shanghai 201203, PR China.
| | - Xu Bai
- The Center for Combinatorial Chemistry and Drug Discovery of Jilin University, The School of Pharmaceutical Sciences, Jilin University, Changchun, Jilin 130021, PR China.
| |
Collapse
|
3
|
El-Kalyoubi SA, Gomaa HAM, Abdelhafez EMN, Ramadan M, Agili F, Youssif BGM. Design, Synthesis, and Anti-Proliferative Action of Purine/Pteridine-Based Derivatives as Dual Inhibitors of EGFR and BRAF V600E. Pharmaceuticals (Basel) 2023; 16:ph16050716. [PMID: 37242499 DOI: 10.3390/ph16050716] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Revised: 04/28/2023] [Accepted: 05/04/2023] [Indexed: 05/28/2023] Open
Abstract
The investigation of novel EGFR and BRAFV600E dual inhibitors is intended to serve as targeted cancer treatment. Two sets of purine/pteridine-based derivatives were designed and synthesized as EGFR/BRAFV600E dual inhibitors. The majority of the compounds exhibited promising antiproliferative activity on the cancer cell lines tested. Compounds 5a, 5e, and 7e of purine-based and pteridine-based scaffolds were identified as the most potent hits in anti-proliferative screening, with GI50 values of 38 nM, 46 nM, and 44 nM, respectively. Compounds 5a, 5e, and 7e demonstrated promising EGFR inhibitory activity, with IC50 values of 87 nM, 98 nM, and 92 nM, respectively, when compared to erlotinib's IC50 value of 80 nM. According to the results of the BRAFV600E inhibitory assay, BRAFV600E may not be a viable target for this class of organic compounds. Finally, molecular docking studies were carried out at the EGFR and BRAFV600E active sites to suggest possible binding modes.
Collapse
Affiliation(s)
- Samar A El-Kalyoubi
- Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Port Said University, Port Said 42511, Egypt
| | - Hesham A M Gomaa
- Department of Pharmacology, College of Pharmacy, Jouf University, Sakaka 72341, Aljouf, Saudi Arabia
| | | | - Mohamed Ramadan
- Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut 11651, Egypt
| | - Fatimah Agili
- Chemistry Department, Faculty of Science (Female Section), Jazan University, Jazan 82621, Jazan, Saudi Arabia
| | - Bahaa G M Youssif
- Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt
| |
Collapse
|
4
|
Zhang M, Yang Y, Wang Y, Wang J, Wu H, Zhu Y. Synthesis and Evaluation of 2-Amine-4-oxyphosaniline Pyrimidine Derivatives as EGFR L858R/T790M/C797S Mutant Inhibitors. Chem Pharm Bull (Tokyo) 2023; 71:140-147. [PMID: 36517026 DOI: 10.1248/cpb.c22-00653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Epidermal growth factor receptor (EGFR) C797S mutation leads to Osimertinib drug resistance by disturbing the covalent biding of Michael acceptor group to the Cys797 residue in the ATP biding cleft. In this manuscript, a class of 2-amine-4-oxyphosaniline pyrimidine derivatives were designed, synthesized and evaluated as new noncovalent reversible EGFR inhibitors against L858R/T790M/C797S (CTL) triple mutant. The kinases inhibitiory activity evaluation showed that four compounds exhibited significant inhibitory activities against CTL (IC50 < 30 nM). In particularly, the most promising compound 7a showed excellent enzymatic inhibitory activity against CTL with IC50 value of 9.9 nM, which was more potent than control compound Osimertinib. Moreover, cell proliferation assays indicated that 7a effectively inhibited H1975-EGFR L858R/T790M/C797S with IC50 value of 0.33 µM. Furthermore, compound 7a displayed good metabolic stabilities in human, rat and mouse liver microsomes, and the putative biding mode of compound 7a with ATP was revealed by molecular docking study. These findings strongly indicated that compound 7a was a promising L858R/T790M/C797S mutant EGFR inhibitor.
Collapse
Affiliation(s)
| | - Yang Yang
- Jiangsu Chia Tai Fenghai Pharmaceutical Co. Ltd
| | - Yunyun Wang
- School of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University
| | - Jia Wang
- Jiangsu Chia Tai Fenghai Pharmaceutical Co. Ltd
| | | | - Yongqiang Zhu
- Jiangsu Chia Tai Fenghai Pharmaceutical Co. Ltd.,College of Life Science, Nanjing Normal University
| |
Collapse
|
5
|
Hashem HE, Amr AEGE, Nossier ES, Anwar MM, Azmy EM. New Benzimidazole-, 1,2,4-Triazole-, and 1,3,5-Triazine-Based Derivatives as Potential EGFR WT and EGFR T790M Inhibitors: Microwave-Assisted Synthesis, Anticancer Evaluation, and Molecular Docking Study. ACS OMEGA 2022; 7:7155-7171. [PMID: 35252706 PMCID: PMC8892849 DOI: 10.1021/acsomega.1c06836] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/03/2021] [Accepted: 01/24/2022] [Indexed: 06/12/2023]
Abstract
A new series of benzimidazole, 1,2,4-triazole, and 1,3,5-triazine derivatives were designed and synthesized using a microwave irradiation synthetic approach utilizing 2-phenylacetyl isothiocyanate (1) as a key starting material. All the new analogues were evaluated as anticancer agents against a panel of cancer cell lines utilizing doxorubicin as a standard drug. Most of the tested derivatives exhibited selective cytotoxic activity against MCF-7 and A-549 cancer cell lines. Furthermore, the new target compounds 5, 6, and 7 as the most potent antiproliferative agents have been assessed as in vitro EGFRWT and EGFRT790M inhibitors compared to the reference drugs erlotinib and AZD9291. They represented more potent suppression activity against the mutated EGFRT790M than the wild-type EGFRWT. Moreover, the compounds 5, 6, and 7 down-regulated the oncogenic parameter p53 ubiquitination. A docking simulation of compound 6b was carried out to correlate its molecular structure with its significant EGFR inhibition potency and its possible binding interactions within the active site of EGFRWT and the mutant EGFRT790M.
Collapse
Affiliation(s)
- Heba E. Hashem
- Department
of Chemistry, Faculty of Women, Ain Shams
University, Heliopolis, Cairo 11757, Egypt
| | - Abd El-Galil E. Amr
- Pharmaceutical
Chemistry Department, Drug Exploration & Development Chair (DEDC),
College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
- Applied
Organic Chemistry Department, National Research
Center, Dokki, Cairo 12622, Egypt
| | - Eman S. Nossier
- Pharmaceutical
Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy
(Girls), Al-Azhar University, Cairo 11754, Egypt
| | - Manal M. Anwar
- Department
of Therapeutic Chemistry, National Research
Centre, Dokki, Cairo 12622, Egypt
| | - Eman M. Azmy
- Department
of Chemistry, Faculty of Women, Ain Shams
University, Heliopolis, Cairo 11757, Egypt
| |
Collapse
|
6
|
van der Westhuizen L, Weisner J, Taher A, Landel I, Quambusch L, Lindemann M, Uhlenbrock N, Müller MP, Green IR, Pelly SC, Rauh D, van Otterlo WAL. Covalent allosteric inhibitors of Akt generated using a click fragment approach. ChemMedChem 2022; 17:e202100776. [PMID: 35170857 PMCID: PMC9311865 DOI: 10.1002/cmdc.202100776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2021] [Revised: 02/14/2022] [Indexed: 11/30/2022]
Abstract
Akt is a protein kinase that has been implicated in the progression of cancerous tumours. A number of covalent allosteric Akt inhibitors are known, and based on these scaffolds, a small library of novel potential covalent allosteric imidazopyridine‐based inhibitors was designed. The envisaged compounds were synthesised, with click chemistry enabling a modular approach to a number of the target compounds. The binding modes, potencies and antiproliferative activities of these synthesised compounds were explored, thereby furthering the structure activity relationship knowledge of this class of Akt inhibitors. Three novel covalent inhibitors were identified, exhibiting moderate activity against Akt1 and various cancer cell lines, potentially paving the way for future covalent allosteric inhibitors with improved properties.
Collapse
Affiliation(s)
| | - Jörn Weisner
- TU Dortmund: Technische Universitat Dortmund, Chemistry and Chemical Biology, GERMANY
| | - Abu Taher
- Stellenbosch University, Chemistry and Polymer Science, SOUTH AFRICA
| | - Ina Landel
- TU Dortmund: Technische Universitat Dortmund, Chemistry and Chemical Biology, GERMANY
| | - Lena Quambusch
- TU Dortmund: Technische Universitat Dortmund, Chemistry and Chemical Biology, GERMANY
| | - Marius Lindemann
- TU Dortmund: Technische Universitat Dortmund, Chemistry and Chemical Biology, GERMANY
| | - Niklas Uhlenbrock
- TU Dortmund: Technische Universitat Dortmund, Chemistry and Chemical Biology, GERMANY
| | - Matthias P Müller
- TU Dortmund: Technische Universitat Dortmund, Chemistry and Chemical Biology, GERMANY
| | - Ivan R Green
- Stellenbosch University, Chemistry and Polymer Science, SOUTH AFRICA
| | | | - Daniel Rauh
- TU Dortmund: Technische Universitat Dortmund, Chemistry and Chemical Biology, GERMANY
| | - Willem A L van Otterlo
- Stellenbosch University, Department of Chemistry and Polymer Sciences, Department of Chemistry and Polyme, Merriman Street, 7602, Stellenbosch, SOUTH AFRICA
| |
Collapse
|
7
|
Dou D, Diao Y, Sha W, Su R, Tong L, Li W, Leng L, Xie L, Yu Z, Song H, Shen Z, Zhu L, Zhao Z, Xie H, Chen Z, Li H, Xu Y. Discovery of Pteridine-7(8 H)-one Derivatives as Potent and Selective Inhibitors of Bruton's Tyrosine Kinase (BTK). J Med Chem 2022; 65:2694-2709. [PMID: 35099969 DOI: 10.1021/acs.jmedchem.1c02208] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Bruton's tyrosine kinase (BTK) is an attractive therapeutic target in the treatment of cancer, inflammation, and autoimmune diseases. Covalent and noncovalent BTK inhibitors have been developed, among which covalent BTK inhibitors have shown great clinical efficacy. However, some of them could produce adverse effects, such as diarrhea, rash, and platelet dysfunction, which are associated with the off-target inhibition of ITK and EGFR. In this study, we disclosed a series of pteridine-7(8H)-one derivatives as potent and selective covalent BTK inhibitors, which were optimized from 3z, an EGFR inhibitor previously reported by our group. Among them, compound 24a exhibited great BTK inhibition activity (IC50 = 4.0 nM) and high selectivity in both enzymatic (ITK >250-fold, EGFR >2500-fold) and cellular levels (ITK >227-fold, EGFR 27-fold). In U-937 xenograft models, 24a significantly inhibited tumor growth (TGI = 57.85%) at a 50 mg/kg dosage. Accordingly, 24a is a new BTK inhibitor worthy of further development.
Collapse
Affiliation(s)
- Dou Dou
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Yanyan Diao
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Wenjie Sha
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Rongrong Su
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Linjiang Tong
- Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| | - Wenjie Li
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Limin Leng
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Lijuan Xie
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Zhixiao Yu
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Haoming Song
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Zihao Shen
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Lili Zhu
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Zhenjiang Zhao
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Hua Xie
- Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| | - Zhuo Chen
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Honglin Li
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Yufang Xu
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| |
Collapse
|
8
|
Li W, Zhang J, Wang M, Dong R, Zhou X, Zheng X, Sun L. Pyrimidine-fused Dinitrogenous Penta-heterocycles as a Privileged Scaffold for Anti-Cancer Drug Discovery. Curr Top Med Chem 2022; 22:284-304. [PMID: 35021973 DOI: 10.2174/1568026622666220111143949] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2021] [Revised: 12/30/2021] [Accepted: 12/30/2021] [Indexed: 11/22/2022]
Abstract
Pyrimidine-fused derivatives that are the inextricable part of DNA and RNA play a key role in the normal life cycle of cells. Pyrimidine-fused dinitrogenous penta-heterocycles including pyrazolopyrimidines and imidazopyrimidines is a special class of pyrimidine-fused compounds contributing to an important portion in anti-cancer drug discovery, which have been discovered as core structure for promising anti-cancer agents used in clinic or clinical evaluations. Pyrimidine-fused dinitrogenous penta-heterocycles have become one privileged scaffold for anti-cancer drug discovery. This review consists of the recent progress of pyrimidine-fused dinitrogenous penta-heterocycles as anti-cancer agents and their synthetic strategies. In addition, this review also summarizes some key structure-activity relationships (SARs) of pyrimidine-fused dinitrogenous penta-heterocycle derivatives as anti-cancer agents.
Collapse
Affiliation(s)
- Wen Li
- Jiangsu Key Laboratory of Drug Design & Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, PR China
| | - Jinyang Zhang
- Jiangsu Key Laboratory of Drug Design & Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, PR China
| | - Min Wang
- Jiangsu Key Laboratory of Drug Design & Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, PR China
| | - Ru Dong
- Jiangsu Key Laboratory of Drug Design & Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, PR China
| | - Xin Zhou
- Jiangsu Key Laboratory of Drug Design & Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, PR China
| | - Xin Zheng
- Jiangsu Key Laboratory of Drug Design & Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, PR China
| | - Liping Sun
- Jiangsu Key Laboratory of Drug Design & Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, PR China
| |
Collapse
|
9
|
Building 2D classification models and 3D CoMSIA models on small-molecule inhibitors of both wild-type and T790M/L858R double-mutant EGFR. Mol Divers 2021; 26:1715-1730. [PMID: 34636023 DOI: 10.1007/s11030-021-10300-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2021] [Accepted: 08/17/2021] [Indexed: 10/20/2022]
Abstract
Epidermal growth factor receptor (EGFR) has received widespread attention because it is an important target for anticancer drug design. Mutations in the EGFR, especially the T790M/L858R double mutation, have made cancer treatment more difficult. We herein built the structure-activity relationship models of small-molecule inhibitors on wild-type and T790M/L858R double-mutant EGFR with a whole dataset of 379 compounds. For 2D classification models, we used ECFP4 fingerprints to build support vector machine and random forest models and used SMILES to build self-attention recurrent neural network models. Each of all six models resulted in an accuracy of above 0.87 and the Matthews correlation coefficient value of above 0.76 on the test set, respectively. We concluded that inhibitors containing anilinoquinoline and methoxy or fluoro phenyl are highly active against wild EGFR. Substructures such as anilinopyrimidine, acrylamide, amino phenyl, methoxy phenyl, and thienopyrimidinyl amide appeared more in highly active inhibitors against double-mutant EGFR. We also used self-organizing map to cluster the inhibitors into six subsets based on ECFP4 fingerprints and analyzed the activity characteristics of different scaffolds in each subset. Among them, three datasets, which are based on pteridin, anilinopyrimidine, and anilinoquinoline scaffold, were selected to build 3D comparative molecular similarity analysis models individually. Models with the leave-one-out coefficient of determination (q2) above 0.65 were selected, and five descriptor types (steric, electrostatic, hydrophobic, donor, and acceptor) were used to study the effects of side chains of inhibitors on the activity against wild-type and mutant-type EGFR.
Collapse
|
10
|
Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Mol Divers 2021; 25:1315-1360. [PMID: 33844136 PMCID: PMC8040371 DOI: 10.1007/s11030-021-10217-3] [Citation(s) in RCA: 256] [Impact Index Per Article: 85.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2021] [Accepted: 03/22/2021] [Indexed: 02/06/2023]
Abstract
Drug designing and development is an important area of research for pharmaceutical companies and chemical scientists. However, low efficacy, off-target delivery, time consumption, and high cost impose a hurdle and challenges that impact drug design and discovery. Further, complex and big data from genomics, proteomics, microarray data, and clinical trials also impose an obstacle in the drug discovery pipeline. Artificial intelligence and machine learning technology play a crucial role in drug discovery and development. In other words, artificial neural networks and deep learning algorithms have modernized the area. Machine learning and deep learning algorithms have been implemented in several drug discovery processes such as peptide synthesis, structure-based virtual screening, ligand-based virtual screening, toxicity prediction, drug monitoring and release, pharmacophore modeling, quantitative structure-activity relationship, drug repositioning, polypharmacology, and physiochemical activity. Evidence from the past strengthens the implementation of artificial intelligence and deep learning in this field. Moreover, novel data mining, curation, and management techniques provided critical support to recently developed modeling algorithms. In summary, artificial intelligence and deep learning advancements provide an excellent opportunity for rational drug design and discovery process, which will eventually impact mankind. The primary concern associated with drug design and development is time consumption and production cost. Further, inefficiency, inaccurate target delivery, and inappropriate dosage are other hurdles that inhibit the process of drug delivery and development. With advancements in technology, computer-aided drug design integrating artificial intelligence algorithms can eliminate the challenges and hurdles of traditional drug design and development. Artificial intelligence is referred to as superset comprising machine learning, whereas machine learning comprises supervised learning, unsupervised learning, and reinforcement learning. Further, deep learning, a subset of machine learning, has been extensively implemented in drug design and development. The artificial neural network, deep neural network, support vector machines, classification and regression, generative adversarial networks, symbolic learning, and meta-learning are examples of the algorithms applied to the drug design and discovery process. Artificial intelligence has been applied to different areas of drug design and development process, such as from peptide synthesis to molecule design, virtual screening to molecular docking, quantitative structure-activity relationship to drug repositioning, protein misfolding to protein-protein interactions, and molecular pathway identification to polypharmacology. Artificial intelligence principles have been applied to the classification of active and inactive, monitoring drug release, pre-clinical and clinical development, primary and secondary drug screening, biomarker development, pharmaceutical manufacturing, bioactivity identification and physiochemical properties, prediction of toxicity, and identification of mode of action.
Collapse
Affiliation(s)
- Rohan Gupta
- Molecular Neuroscience and Functional Genomics Laboratory, Department of Biotechnology, Delhi Technological University (Formerly DCE), Shahbad Daulatpur, Bawana Road, Delhi, 110042, India
| | - Devesh Srivastava
- Molecular Neuroscience and Functional Genomics Laboratory, Department of Biotechnology, Delhi Technological University (Formerly DCE), Shahbad Daulatpur, Bawana Road, Delhi, 110042, India
| | - Mehar Sahu
- Molecular Neuroscience and Functional Genomics Laboratory, Department of Biotechnology, Delhi Technological University (Formerly DCE), Shahbad Daulatpur, Bawana Road, Delhi, 110042, India
| | - Swati Tiwari
- Molecular Neuroscience and Functional Genomics Laboratory, Department of Biotechnology, Delhi Technological University (Formerly DCE), Shahbad Daulatpur, Bawana Road, Delhi, 110042, India
| | - Rashmi K Ambasta
- Molecular Neuroscience and Functional Genomics Laboratory, Department of Biotechnology, Delhi Technological University (Formerly DCE), Shahbad Daulatpur, Bawana Road, Delhi, 110042, India
| | - Pravir Kumar
- Molecular Neuroscience and Functional Genomics Laboratory, Department of Biotechnology, Delhi Technological University (Formerly DCE), Shahbad Daulatpur, Bawana Road, Delhi, 110042, India.
| |
Collapse
|
11
|
Li J, An B, Song X, Zhang Q, Chen C, Wei S, Fan R, Li X, Zou Y. Design, synthesis and biological evaluation of novel 2,4-diaryl pyrimidine derivatives as selective EGFR L858R/T790M inhibitors. Eur J Med Chem 2020; 212:113019. [PMID: 33429247 DOI: 10.1016/j.ejmech.2020.113019] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2020] [Revised: 10/19/2020] [Accepted: 11/10/2020] [Indexed: 12/24/2022]
Abstract
Lung cancer is the leading cause of cancer deaths. It has been demonstrated that epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) are efficacious in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). In this work, a new series of 2,4-diaryl pyrimidine derivatives containing cyclopropyl moiety were designed, synthesized and evaluated as novel selective EGFRL858R/T790M inhibitors. The most promising compound, 8l demonstrated excellent kinase inhibitory activity against EGFR double mutation with IC50 value of 0.26 nM. Moreover, 8l provided strong activity against H1975 cells with IC50 value of 0.008 μM and exhibited little toxicity toward four non-tumorigenic cell lines. Furthermore, 8l showed potent anti-tumor efficacy in a murine EGFRL858R/T790M-driven H1975 xenograft model. These results indicated that 8l may be a promising drug candidate for further study.
Collapse
Affiliation(s)
- Jianheng Li
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China
| | - Baijiao An
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China
| | - Xianheng Song
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China
| | - Qianzhong Zhang
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China
| | - Chun Chen
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China
| | - Shuxian Wei
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China
| | - Runzhu Fan
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China
| | - Xingshu Li
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China; Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, Guangzhou 510000, PR China
| | - Yong Zou
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China; Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, Guangzhou 510000, PR China.
| |
Collapse
|
12
|
Abstract
Fms-like tyrosine kinase-3 (FLT3) mutations occur in approximately 30% of acute myeloid leukemia (AML) cases, suggesting FLT3 as an attractive target for AML treatment. Early FLT3 inhibitors enhance antileukemia efficacy by inhibiting multiple targets, and thus had stronger off-target activity, increasing their toxicity. Recently, a number of potent and selective FLT3 inhibitors have been developed, many of which are effective against multiple mutations. This review outlines the evolution of AML-targeting FLT3 inhibitors by focusing on their chemotypes, selectivity and activity over FLT3 wild-type and FLT3 mutations as well as new techniques related to FLT3. Compounds that currently enter the late clinical stage or have entered the market are also briefly reported.
Collapse
|
13
|
Cheng W, Wang S, Yang Z, Tian X, Hu Y. Design, synthesis, and biological study of 4-[(2-nitroimidazole-1 H-alkyloxyl)aniline]-quinazolines as EGFR inhibitors exerting cytotoxicities both under normoxia and hypoxia. DRUG DESIGN DEVELOPMENT AND THERAPY 2019; 13:3079-3089. [PMID: 31695326 PMCID: PMC6717862 DOI: 10.2147/dddt.s209481] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/20/2019] [Accepted: 07/22/2019] [Indexed: 11/23/2022]
Abstract
Purpose In order to get novel EGFR inhibitors exerting more potency in tumor hypoxia than in normoxia. Methods A series of 4-[(2-nitroimidazole-1H-alkyloxyl)aniline]-quinazolines were designed and synthesized, and their in vitro cytotoxicity and EGFR inhibitory activity were evaluated. Molecule docking study was performed for the representative compound. Results The structure-activity relationship (SAR) studies revealed that compounds bearing both meta-chloride and para-(2-nitroimidazole-1H-alkyloxy) groups on the aniline displayed potent inhibitory activities both in enzymatic and cellular levels. The most promising compound 16i potently inhibited EGFR with an IC50 value of 0.12 μM. Meanwhile, it manifested more potent cytotoxicity than the positive control lapatinib under tumor normoxia and hypoxia conditions (IC50 values of 1.59 and 1.09 μM against A549 cells, 2.46 and 1.35 μM against HT-29 cells, respectively). The proposed binding model of 16i in complex with EGFR was displayed by the docking results. Conclusion This study provides insights for developing hypoxia-activated kinase inhibitors.
Collapse
Affiliation(s)
- Weiyan Cheng
- Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, People's Republic of China.,Henan Key Laboratory of Precision Clinical Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
| | - Suhua Wang
- Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, People's Republic of China.,Henan Key Laboratory of Precision Clinical Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
| | - Zhiheng Yang
- Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, People's Republic of China.,Henan Key Laboratory of Precision Clinical Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
| | - Xin Tian
- Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, People's Republic of China.,Henan Key Laboratory of Precision Clinical Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
| | - Yongzhou Hu
- Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, People's Republic of China
| |
Collapse
|
14
|
He G, Song Y, Wei W, Wang X, Lu X, Li H. eSHAFTS: Integrated and graphical drug design software based on 3D molecular similarity. J Comput Chem 2019; 40:826-838. [DOI: 10.1002/jcc.25769] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2018] [Revised: 10/17/2018] [Accepted: 11/23/2018] [Indexed: 12/22/2022]
Affiliation(s)
- Gaoqi He
- Department of Computer Science and Engineering; East China University of Science and Technology; Shanghai 200237 China
- School of Computer Science and Software Engineering; East China Normal University; Shanghai 200062 China
| | - Yiping Song
- Department of Computer Science and Engineering; East China University of Science and Technology; Shanghai 200237 China
| | - Wenhao Wei
- Department of Computer Science and Engineering; East China University of Science and Technology; Shanghai 200237 China
| | - Xia Wang
- Shanghai Key Laboratory of New Drug Design; East China University of Science and Technology; Shanghai 200237 China
| | - Xingjian Lu
- Department of Computer Science and Engineering; East China University of Science and Technology; Shanghai 200237 China
| | - Honglin Li
- Shanghai Key Laboratory of New Drug Design; East China University of Science and Technology; Shanghai 200237 China
| |
Collapse
|
15
|
A review of ligand-based virtual screening web tools and screening algorithms in large molecular databases in the age of big data. Future Med Chem 2018; 10:2641-2658. [PMID: 30499744 DOI: 10.4155/fmc-2018-0076] [Citation(s) in RCA: 45] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Virtual screening has become a widely used technique for helping in drug discovery processes. The key to this success is its ability to aid in the identification of novel bioactive compounds by screening large molecular databases. Several web servers have emerged in the last few years supplying platforms to guide users in screening publicly accessible chemical databases in a reasonable time. In this review, we discuss a representative set of online virtual screening servers and their underlying similarity algorithms. Other related topics, such as molecular representation or freely accessible databases are also treated. The most relevant contributions to this review arise from critical discussions concerning the pros and cons of servers and algorithms, and the challenges that future works must solve in a virtual screening framework.
Collapse
|
16
|
Carmona-Martínez V, Ruiz-Alcaraz AJ, Vera M, Guirado A, Martínez-Esparza M, García-Peñarrubia P. Therapeutic potential of pteridine derivatives: A comprehensive review. Med Res Rev 2018; 39:461-516. [PMID: 30341778 DOI: 10.1002/med.21529] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2018] [Revised: 07/07/2018] [Accepted: 07/10/2018] [Indexed: 12/19/2022]
Abstract
Pteridines are aromatic compounds formed by fused pyrazine and pyrimidine rings. Many living organisms synthesize pteridines, where they act as pigments, enzymatic cofactors, or immune system activation molecules. This variety of biological functions has motivated the synthesis of a huge number of pteridine derivatives with the aim of studying their therapeutic potential. This review gathers the state-of-the-art of pteridine derivatives, describing their biological activities and molecular targets. The antitumor activity of pteridine-based compounds is one of the most studied and advanced therapeutic potentials, for which several molecular targets have been identified. Nevertheless, pteridines are also considered as very promising therapeutics for the treatment of chronic inflammation-related diseases. On the other hand, many pteridine derivatives have been tested for antimicrobial activities but, although some of them resulted to be active in preliminary assays, a deeper research is needed in this area. Moreover, pteridines may be of use in the treatment of many other diseases, such as diabetes, osteoporosis, ischemia, or neurodegeneration, among others. Thus, the diversity of the biological activities shown by these compounds highlights the promising therapeutic use of pteridine derivatives. Indeed, methotrexate, pralatrexate, and triamterene are Food and Drug Administration approved pteridines, while many others are currently under study in clinical trials.
Collapse
Affiliation(s)
- Violeta Carmona-Martínez
- Departamento de Bioquímica, Biología Molecular (B) e Inmunología, Facultad de Medicina, IMIB and Regional Campus of International Excellence "Campus Mare Nostrum," Universidad de Murcia, Murcia, Spain
| | - Antonio J Ruiz-Alcaraz
- Departamento de Bioquímica, Biología Molecular (B) e Inmunología, Facultad de Medicina, IMIB and Regional Campus of International Excellence "Campus Mare Nostrum," Universidad de Murcia, Murcia, Spain
| | - María Vera
- Departamento de Química Orgánica, Universidad de Murcia, Campus de Espinardo, Murcia, Spain
| | - Antonio Guirado
- Departamento de Química Orgánica, Universidad de Murcia, Campus de Espinardo, Murcia, Spain
| | - María Martínez-Esparza
- Departamento de Bioquímica, Biología Molecular (B) e Inmunología, Facultad de Medicina, IMIB and Regional Campus of International Excellence "Campus Mare Nostrum," Universidad de Murcia, Murcia, Spain
| | - Pilar García-Peñarrubia
- Departamento de Bioquímica, Biología Molecular (B) e Inmunología, Facultad de Medicina, IMIB and Regional Campus of International Excellence "Campus Mare Nostrum," Universidad de Murcia, Murcia, Spain
| |
Collapse
|
17
|
Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3,4-d]pyrimidine scaffold. Bioorg Med Chem 2018; 26:3619-3633. [DOI: 10.1016/j.bmc.2018.05.039] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2018] [Revised: 05/21/2018] [Accepted: 05/23/2018] [Indexed: 01/09/2023]
|
18
|
Hao Y, Lyu J, Qu R, Tong Y, Sun D, Feng F, Tong L, Yang T, Zhao Z, Zhu L, Ding J, Xu Y, Xie H, Li H. Design, Synthesis, and Biological Evaluation of Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation. J Med Chem 2018; 61:5609-5622. [DOI: 10.1021/acs.jmedchem.8b00346] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Affiliation(s)
- Yongjia Hao
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
- School of Pharmacy, Guizhou University of Chinese Medicine, Guiyang 550025, China
| | - Jiankun Lyu
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Rong Qu
- Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| | - Yi Tong
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Deheng Sun
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Fang Feng
- Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| | - Linjiang Tong
- Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| | - Tingyuan Yang
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Zhenjiang Zhao
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Lili Zhu
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Jian Ding
- Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| | - Yufang Xu
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Hua Xie
- Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| | - Honglin Li
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| |
Collapse
|
19
|
Zhang H, Wang J, Shen Y, Wang HY, Duan WM, Zhao HY, Hei YY, Xin M, Cao YX, Zhang SQ. Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs. Eur J Med Chem 2018; 148:221-237. [DOI: 10.1016/j.ejmech.2018.02.051] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2018] [Revised: 02/14/2018] [Accepted: 02/14/2018] [Indexed: 12/19/2022]
|
20
|
Sheng J, Liu Z, Yan M, Zhang X, Wang D, Xu J, Zhang E, Zou Y. Biomass-involved synthesis of N-substituted benzofuro[2,3-d]pyrimidine-4-amines and biological evaluation as novel EGFR tyrosine kinase inhibitors. Org Biomol Chem 2018; 15:4971-4977. [PMID: 28548166 DOI: 10.1039/c7ob00793k] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Shikimic acid (1) is a renewable biomass which could be obtained sustainably through natural product isolation or metabolic engineering. Owing to its great potential in chemical conversion, the value-added utilization of this non-grain biomass has received much attention in recent years. Based on the established transformation route from shikimic acid (1) to methyl 3-dehydroshikimate (3-MDHS, 2) and to the multi-functionalized methyl 2-amino-3-cyanobenzofuran-5-carboxylate (3), we disclose a facile and transition metal-free method to access a series of N-substituted benzofuro[2,3-d]pyrimidine-4-amines in 63%-90% yields. The identification of these compounds as EGFR tyrosine kinase inhibitors has also been described. Among them, compound 5h exhibited the most potent inhibitory effect against EGFR tyrosine kinase with an IC50 of 1.7 nM and excellent antiproliferative activity against A431 and A549 cell lines with a GI50 of 5.1 and 12.3 μM, respectively.
Collapse
Affiliation(s)
- Jianfei Sheng
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, People's Republic of China.
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Perez CE, Park HB, Crawford JM. Functional Characterization of a Condensation Domain That Links Nonribosomal Peptide and Pteridine Biosynthetic Machineries in Photorhabdus luminescens. Biochemistry 2018; 57:354-361. [PMID: 29111689 DOI: 10.1021/acs.biochem.7b00863] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Nonribosomal peptide synthetases (NRPSs) produce a wide variety of biologically important small molecules. NRPSs can interface with other enzymes to form hybrid biosynthetic systems that expand the structural and functional diversity of their products. The pepteridines are metabolites encoded by an unprecedented pteridine-NRPS-type hybrid biosynthetic gene cluster in Photorhabdus luminescens, but how the distinct enzymatic systems interface to produce these molecules has not been examined at the biochemical level. By an unknown mechanism, the genetic locus can also affect the regulation of other enzymes involved in autoinducer and secondary metabolite biosynthesis. Here, through in vitro protein biochemical assays, we demonstrate that an atypical NRPS condensation (C) domain present in the pathway condenses acyl units derived from α-keto acids onto a free 5,6,7,8-tetrahydropterin core, producing the tertiary cis-amide-containing pepteridines. Solution studies of the chemically synthesized molecules led to the same amide regiochemistries that were observed in the natural products. The biochemical transformations mediated by the C domain destroy the radical scavenging activity of its redox active tetrahydropterin substrate. Secondary metabolite analyses revealed that the pepteridine locus affects select metabolic pathways associated with quorum sensing, antibiosis, and symbiosis. Taken together, the results suggest that the pathway likely regulates cellular redox and specialized metabolic pathways through engagement with the citric acid cycle.
Collapse
Affiliation(s)
- Corey E Perez
- Department of Chemistry, Yale University , New Haven, Connecticut 06520, United States.,Chemical Biology Institute, Yale University , West Haven, Connecticut 06516, United States
| | - Hyun Bong Park
- Department of Chemistry, Yale University , New Haven, Connecticut 06520, United States.,Chemical Biology Institute, Yale University , West Haven, Connecticut 06516, United States
| | - Jason M Crawford
- Department of Chemistry, Yale University , New Haven, Connecticut 06520, United States.,Chemical Biology Institute, Yale University , West Haven, Connecticut 06516, United States.,Department of Microbial Pathogenesis, Yale School of Medicine , New Haven, Connecticut 06510, United States
| |
Collapse
|
22
|
Synthesis and preliminary antiproliferative activity of new pteridin-7(8H)-one derivatives. Eur J Med Chem 2018; 143:1396-1405. [DOI: 10.1016/j.ejmech.2017.10.037] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2017] [Revised: 10/11/2017] [Accepted: 10/13/2017] [Indexed: 11/19/2022]
|
23
|
Chen D, Guo D, Yan Z, Zhao Y. Allenamide as a bioisostere of acrylamide in the design and synthesis of targeted covalent inhibitors. MEDCHEMCOMM 2017; 9:244-253. [PMID: 30108918 DOI: 10.1039/c7md00571g] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/12/2017] [Accepted: 12/10/2017] [Indexed: 12/13/2022]
Abstract
The success of acrylamide-containing drugs in treating cancers has spurred a passion to search for acrylamide bioisosteres. In our endeavour, we have identified that an allenamide group can be a reactive bioisostere of the acrylamide group. In our development of allenamide-containing compounds, we found that the most potent compound, 14, inhibited the kinase activities of both T790M/L858R double mutant and wild type EGFR in a low nM range. 14 also inhibited the growth of NCI-H1975 lung cancer cells at IC50 = 33 nM, which is comparable to that of acrylamide-containing osimertinib. The western blot analysis showed that the phosphorylation of EGFR, AKT, and ERK1/2 was simultaneously inhibited in a dose-dependent manner when NCI-H1975 cells were treated with 14. By measuring the conjugate addition product formed by 14 and GSH, we obtained a reaction rate constant of 302.5 × 10-3 min-1, which is about 30-fold higher than that of osimertinib. Taken together, our data suggest that the allenamide-containing compounds inhibited EGFR kinases through covalent modifications. Our study indicates that the allenamide group could serve as an alternative electrophilic warhead in the design of targeted covalent inhibitors, and this bioisostere replacement may have broad applications in medicinal chemistry.
Collapse
Affiliation(s)
- Deheng Chen
- State Key Laboratory of Drug Research , Shanghai Institute of Materia Medica , Chinese Academy of Sciences , 555 Zuchongzhi Road , Shanghai 201203 , China . .,University of Chinese Academy of Sciences , Beijing 100049 , China
| | - Dexiang Guo
- State Key Laboratory of Drug Research , Shanghai Institute of Materia Medica , Chinese Academy of Sciences , 555 Zuchongzhi Road , Shanghai 201203 , China .
| | - Ziqin Yan
- State Key Laboratory of Drug Research , Shanghai Institute of Materia Medica , Chinese Academy of Sciences , 555 Zuchongzhi Road , Shanghai 201203 , China .
| | - Yujun Zhao
- State Key Laboratory of Drug Research , Shanghai Institute of Materia Medica , Chinese Academy of Sciences , 555 Zuchongzhi Road , Shanghai 201203 , China .
| |
Collapse
|
24
|
Geng PF, Wang CC, Li ZH, Hu XN, Zhao TQ, Fu DJ, Zhao B, Yu B, Liu HM. Design, synthesis and preliminary biological evaluation of 5,8-dihydropteridine-6,7-diones that induce apoptosis and suppress cell migration. Eur J Med Chem 2017; 143:1959-1967. [PMID: 29133051 DOI: 10.1016/j.ejmech.2017.11.009] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2017] [Revised: 10/12/2017] [Accepted: 11/03/2017] [Indexed: 12/26/2022]
Abstract
Pteridines are an important class of fused heterocycles found in natural products and drug molecules, and have shown diverse biological activities. A focused library of 5,8-dihydropteridine-6,7-dione derivatives were designed and evaluated for their antiproliferative activity against MGC-803, SGC-7901, A549 and PC-3 cancer cell lines. The SARs studies highlighted the importance of the piperazine substituted 5,8-dihydropteridine-6,7-dione frameworks for the activity and revealed essential structural elements. Among these compounds, compound 5n displayed the most potent and broad-spectrum antiproliferative inhibition against the tested cell lines and was sensitive to MGC-803 cell line, slightly more potent than 5-FU. Preliminary mechanistic studies showed that compound 5n could inhibit the colony formation and migration of MGC-803 cells. Besides, flow cytometry analysis showed that compound 5n concentration-dependently induced apoptosis of MGC-803 cells. Our studies suggest that the piperazine substituted 5,8-dihydropteridine-6,7-dione frameworks may be regarded as new chemotypes for designing effective antitumor agents targeting gastric cancer cells.
Collapse
Affiliation(s)
- Peng-Fei Geng
- Key Laboratory of Advanced Drug Preparation Technologies (Zhengzhou University), Ministry of Education, Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, PR China; Key Laboratory of Henan Province for Drug Quality and Evaluation, PR China
| | - Cong-Cong Wang
- Key Laboratory of Advanced Drug Preparation Technologies (Zhengzhou University), Ministry of Education, Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, PR China; Key Laboratory of Henan Province for Drug Quality and Evaluation, PR China
| | - Zhong-Hua Li
- Key Laboratory of Advanced Drug Preparation Technologies (Zhengzhou University), Ministry of Education, Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, PR China; Key Laboratory of Henan Province for Drug Quality and Evaluation, PR China
| | - Xiao-Ning Hu
- Key Laboratory of Advanced Drug Preparation Technologies (Zhengzhou University), Ministry of Education, Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, PR China; Key Laboratory of Henan Province for Drug Quality and Evaluation, PR China
| | - Tao-Qian Zhao
- Key Laboratory of Advanced Drug Preparation Technologies (Zhengzhou University), Ministry of Education, Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, PR China; Key Laboratory of Henan Province for Drug Quality and Evaluation, PR China
| | - Dong-Jun Fu
- Key Laboratory of Advanced Drug Preparation Technologies (Zhengzhou University), Ministry of Education, Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, PR China; Key Laboratory of Henan Province for Drug Quality and Evaluation, PR China
| | - Bing Zhao
- Key Laboratory of Advanced Drug Preparation Technologies (Zhengzhou University), Ministry of Education, Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, PR China; Key Laboratory of Henan Province for Drug Quality and Evaluation, PR China
| | - Bin Yu
- Key Laboratory of Advanced Drug Preparation Technologies (Zhengzhou University), Ministry of Education, Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, PR China; Key Laboratory of Henan Province for Drug Quality and Evaluation, PR China.
| | - Hong-Min Liu
- Key Laboratory of Advanced Drug Preparation Technologies (Zhengzhou University), Ministry of Education, Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, PR China; Key Laboratory of Henan Province for Drug Quality and Evaluation, PR China.
| |
Collapse
|
25
|
Chen L, Fu W, Feng C, Qu R, Tong L, Zheng L, Fang B, Qiu Y, Hu J, Cai Y, Feng J, Xie H, Ding J, Liu Z, Liang G. Structure-based design and synthesis of 2,4-diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC. Eur J Med Chem 2017; 140:510-527. [DOI: 10.1016/j.ejmech.2017.08.061] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2017] [Revised: 08/25/2017] [Accepted: 08/28/2017] [Indexed: 01/06/2023]
|
26
|
Zhang WY, Lu WC, Jiang H, Lv ZB, Xie YQ, Lian FL, Liang ZJ, Jiang YX, Wang DJ, Luo C, Jin J, Ye F. Discovery of alkyl bis(oxy)dibenzimidamide derivatives as novel protein arginine methyltransferase 1 (PRMT1) inhibitors. Chem Biol Drug Des 2017. [DOI: 10.1111/cbdd.13047] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Affiliation(s)
- Wei-yao Zhang
- College of Life Sciences; Zhejiang Sci-Tech University; Hangzhou China
| | - Wen-chao Lu
- Drug Discovery and Design Center; State Key Laboratory of Drug Research; Shanghai Institute of Materia Medica; Chinese Academy of Sciences; Shanghai China
- University of Chinese Academy of Sciences; Beijing China
| | - Hao Jiang
- Drug Discovery and Design Center; State Key Laboratory of Drug Research; Shanghai Institute of Materia Medica; Chinese Academy of Sciences; Shanghai China
- University of Chinese Academy of Sciences; Beijing China
| | - Zheng-bing Lv
- College of Life Sciences; Zhejiang Sci-Tech University; Hangzhou China
| | - Yi-qian Xie
- Drug Discovery and Design Center; State Key Laboratory of Drug Research; Shanghai Institute of Materia Medica; Chinese Academy of Sciences; Shanghai China
| | - Fu-lin Lian
- Drug Discovery and Design Center; State Key Laboratory of Drug Research; Shanghai Institute of Materia Medica; Chinese Academy of Sciences; Shanghai China
| | - Zhong-jie Liang
- Center for Systems Biology; Soochow University; Jiangsu China
| | - Yu-xi Jiang
- School of Pharmacy; Shanghai Jiao Tong University; Shanghai China
| | - Da-jin Wang
- College of Life Sciences; Zhejiang Sci-Tech University; Hangzhou China
| | - Cheng Luo
- Drug Discovery and Design Center; State Key Laboratory of Drug Research; Shanghai Institute of Materia Medica; Chinese Academy of Sciences; Shanghai China
| | - Jia Jin
- College of Life Sciences; Zhejiang Sci-Tech University; Hangzhou China
| | - Fei Ye
- College of Life Sciences; Zhejiang Sci-Tech University; Hangzhou China
- Key Laboratory of Plant Secondary Metabolism and Regulation of Zhejiang Province; Hangzhou China
| |
Collapse
|
27
|
Hao Y, Lyu J, Qu R, Sun D, Zhao Z, Chen Z, Ding J, Xie H, Xu Y, Li H. Structure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors. Sci Rep 2017. [PMID: 28630494 PMCID: PMC5476563 DOI: 10.1038/s41598-017-04184-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Abstract
Epidermal growth factor receptor (EGFR) T790M acquired drug-resistance mutation has become a major clinical challenge for the therapy of non-small cell lung cancer. Here, we applied a structure-guided approach on the basis of the previous reported EGFR inhibitor (compound 9), and designed a series of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-one derivatives as novel mutant-selective EGFR inhibitors. Finally, the most representative compound 20a was identified, which showed high selectivity at both enzymatic and cellular levels against EGFRL858R/T790M (H1975 cell lines) over EGFRWT (A431 cell lines). The representative compound 20a also showed promising antitumor efficiency in the in vivo antitumor efficacy study of H1975 xenograft mouse model driven by EGFRL858R/T790M. These results provide a new scaffold for the treatment of dual-mutant-driven non-small cell lung cancer.
Collapse
Affiliation(s)
- Yongjia Hao
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science & Technology, Shanghai, 200237, China
| | - Jiankun Lyu
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science & Technology, Shanghai, 200237, China
| | - Rong Qu
- Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.,University of Chinese Academy of Sciences, Beijing, 100049, China
| | - Deheng Sun
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science & Technology, Shanghai, 200237, China
| | - Zhenjiang Zhao
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science & Technology, Shanghai, 200237, China
| | - Zhuo Chen
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science & Technology, Shanghai, 200237, China
| | - Jian Ding
- Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China
| | - Hua Xie
- Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
| | - Yufang Xu
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science & Technology, Shanghai, 200237, China.
| | - Honglin Li
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science & Technology, Shanghai, 200237, China.
| |
Collapse
|
28
|
Han W, Du Y. Recent Development of the Second and Third Generation Irreversible Epidermal Growth Factor Receptor Inhibitors. Chem Biodivers 2017; 14. [DOI: 10.1002/cbdv.201600372] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2016] [Accepted: 01/10/2017] [Indexed: 01/05/2023]
Affiliation(s)
- Weiwei Han
- School of Chemistry and Pharmaceutical Engineering; Qilu University of Technology; 3501 Daxue Road Jinan 250353 P. R. China
| | - Yongli Du
- School of Chemistry and Pharmaceutical Engineering; Qilu University of Technology; 3501 Daxue Road Jinan 250353 P. R. China
| |
Collapse
|
29
|
Song Z, Huang S, Yu H, Jiang Y, Wang C, Meng Q, Shu X, Sun H, Liu K, Li Y, Ma X. Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC). Eur J Med Chem 2017; 133:329-339. [DOI: 10.1016/j.ejmech.2017.03.083] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2017] [Revised: 03/29/2017] [Accepted: 03/31/2017] [Indexed: 02/06/2023]
|
30
|
Qin MZ, Wang L, Yan S, Ma JJ, Tian Y, Zhao YF, Gong P. Identification of hydrazone moiety-bearing aminopyrimidines as potent antitumor agents with selective inhibition of gefitinib-resistant H1975 cancer cells. CHINESE CHEM LETT 2017. [DOI: 10.1016/j.cclet.2016.11.030] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
31
|
Chang K, Chen JQ, Shi YX, Sun MJ, Li PF, Zhao ZJ, Zhu WP, Li HL, Xu YF, Li BJ, Qian XH. The discovery of new scaffold of plant activators: From salicylic acid to benzotriazole. CHINESE CHEM LETT 2017. [DOI: 10.1016/j.cclet.2017.02.004] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
32
|
Ge Y, Jin Y, Wang C, Zhang J, Tang Z, Peng J, Liu K, Li Y, Zhou Y, Ma X. Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a N,9-Diphenyl-9 H-purin-2-amine Scaffold. ACS Med Chem Lett 2016; 7:1050-1055. [PMID: 27994736 DOI: 10.1021/acsmedchemlett.6b00235] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2016] [Accepted: 09/21/2016] [Indexed: 12/22/2022] Open
Abstract
Based on the pyrimidine skeleton of EGFRT790M inhibitors, a series of N,9-diphenyl-9H-purin-2-amine derivatives were identified as effective BTK inhibitors. Among these compounds, inhibitors 10d, 10i, and 10j, possessing IC50 values of 0.5, 0.5, and 0.4 nM, displayed anti-BTK kinase activity that was as potent as the reference compounds. In particular, compound 10j suppressed the proliferation of two typical B-cell leukemia cell lines expressing high levels of BTK with concentrations of 7.75 and 12.6 μM. The activity of the subject compound as determined by the CCK-8 method and apoptosis analysis validated that inhibitor 10j is slightly more potent than AVL-292 and ibrutinib. The results of these experimental explorations suggested that 10j could serve as a valuable molecule for control of leukemia pending further developments.
Collapse
Affiliation(s)
- Yang Ge
- College
of Pharmacy, Dalian Medical University, Dalian 116044, P. R. China
| | - Yue Jin
- College
of Pharmacy, Dalian Medical University, Dalian 116044, P. R. China
| | - Changyuan Wang
- College
of Pharmacy, Dalian Medical University, Dalian 116044, P. R. China
| | - Jianbin Zhang
- College
of Pharmacy, Dalian Medical University, Dalian 116044, P. R. China
| | - Zeyao Tang
- College
of Pharmacy, Dalian Medical University, Dalian 116044, P. R. China
| | - Jinyong Peng
- College
of Pharmacy, Dalian Medical University, Dalian 116044, P. R. China
| | - Kexin Liu
- College
of Pharmacy, Dalian Medical University, Dalian 116044, P. R. China
| | - Yanxia Li
- Respiratory
Department, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, P. R. China
| | - Youwen Zhou
- Department
of Dermatology and Skin Science, University of British Columbia, Vancouver, BC V5Z 4E8, Canada
| | - Xiaodong Ma
- College
of Pharmacy, Dalian Medical University, Dalian 116044, P. R. China
| |
Collapse
|
33
|
Song Z, Jin Y, Ge Y, Wang C, Zhang J, Tang Z, Peng J, Liu K, Li Y, Ma X. Synthesis and biological evaluation of azole-diphenylpyrimidine derivatives (AzDPPYs) as potent T790M mutant form of epidermal growth factor receptor inhibitors. Bioorg Med Chem 2016; 24:5505-5512. [DOI: 10.1016/j.bmc.2016.09.001] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2016] [Revised: 08/31/2016] [Accepted: 09/01/2016] [Indexed: 12/16/2022]
|
34
|
Hao Y, Wang X, Zhang T, Sun D, Tong Y, Xu Y, Chen H, Tong L, Zhu L, Zhao Z, Chen Z, Ding J, Xie H, Xu Y, Li H. Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation. J Med Chem 2016; 59:7111-24. [DOI: 10.1021/acs.jmedchem.6b00403] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Yongjia Hao
- Shanghai
Key Laboratory of New Drug Design, Shanghai Key Laboratory of Chemical
Biology, State Key Laboratory of Bioreactor Engineering, School of
Pharmacy, East China University of Science and Technology, Shanghai, 200237, China
| | - Xia Wang
- Shanghai
Key Laboratory of New Drug Design, Shanghai Key Laboratory of Chemical
Biology, State Key Laboratory of Bioreactor Engineering, School of
Pharmacy, East China University of Science and Technology, Shanghai, 200237, China
| | - Tao Zhang
- Division
of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China
| | - Deheng Sun
- Shanghai
Key Laboratory of New Drug Design, Shanghai Key Laboratory of Chemical
Biology, State Key Laboratory of Bioreactor Engineering, School of
Pharmacy, East China University of Science and Technology, Shanghai, 200237, China
| | - Yi Tong
- Shanghai
Key Laboratory of New Drug Design, Shanghai Key Laboratory of Chemical
Biology, State Key Laboratory of Bioreactor Engineering, School of
Pharmacy, East China University of Science and Technology, Shanghai, 200237, China
| | - Yuqiong Xu
- Shanghai
Key Laboratory of New Drug Design, Shanghai Key Laboratory of Chemical
Biology, State Key Laboratory of Bioreactor Engineering, School of
Pharmacy, East China University of Science and Technology, Shanghai, 200237, China
| | - Haiyang Chen
- Shanghai
Key Laboratory of New Drug Design, Shanghai Key Laboratory of Chemical
Biology, State Key Laboratory of Bioreactor Engineering, School of
Pharmacy, East China University of Science and Technology, Shanghai, 200237, China
| | - Linjiang Tong
- Division
of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China
| | - Lili Zhu
- Shanghai
Key Laboratory of New Drug Design, Shanghai Key Laboratory of Chemical
Biology, State Key Laboratory of Bioreactor Engineering, School of
Pharmacy, East China University of Science and Technology, Shanghai, 200237, China
| | - Zhenjiang Zhao
- Shanghai
Key Laboratory of New Drug Design, Shanghai Key Laboratory of Chemical
Biology, State Key Laboratory of Bioreactor Engineering, School of
Pharmacy, East China University of Science and Technology, Shanghai, 200237, China
| | - Zhuo Chen
- Shanghai
Key Laboratory of New Drug Design, Shanghai Key Laboratory of Chemical
Biology, State Key Laboratory of Bioreactor Engineering, School of
Pharmacy, East China University of Science and Technology, Shanghai, 200237, China
| | - Jian Ding
- Division
of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China
| | - Hua Xie
- Division
of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China
| | - Yufang Xu
- Shanghai
Key Laboratory of New Drug Design, Shanghai Key Laboratory of Chemical
Biology, State Key Laboratory of Bioreactor Engineering, School of
Pharmacy, East China University of Science and Technology, Shanghai, 200237, China
| | - Honglin Li
- Shanghai
Key Laboratory of New Drug Design, Shanghai Key Laboratory of Chemical
Biology, State Key Laboratory of Bioreactor Engineering, School of
Pharmacy, East China University of Science and Technology, Shanghai, 200237, China
| |
Collapse
|
35
|
Qin X, Li Z, Yang L, Liu P, Hu L, Zeng C, Pan Z. Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant. Bioorg Med Chem 2016; 24:2871-2881. [DOI: 10.1016/j.bmc.2016.01.003] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2015] [Revised: 01/03/2016] [Accepted: 01/04/2016] [Indexed: 12/27/2022]
|
36
|
Sun D, Yang Y, Lyu J, Zhou W, Song W, Zhao Z, Chen Z, Xu Y, Li H. Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants. J Med Chem 2016; 59:6187-200. [PMID: 27266526 DOI: 10.1021/acs.jmedchem.6b00374] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
FLT3 has been validated as a therapeutic target for the treatment of acute myeloid leukemia (AML). In this paper, we describe for the first time, pteridin-7(8H)-one as a scaffold for potent FLT3 inhibitors derived from structural optimizations on irreversible EGFR inhibitors. The representative inhibitor (31) demonstrates single-digit nanomolar inhibition against FLT3 and subnanomolar KD for drug-resistance FLT3 mutants. In profiling of the in vitro tumor cell lines, it shows good selectivity against AML cells harboring FLT3-ITD mutations over other leukemia and solid tumor cell lines. The mechanism of action study illustrates that pteridin-7(8H)-one derivatives suppress the phosphorylation of FLT3 and its downstream pathways, thereby inducing G0/G1 cell cycle arrest and apoptosis in AML cells. In in vivo studies, 31 significantly suppresses the tumor growth in MV4-11 xenograft model. Overall, we provide a structurally distinct chemical scaffold with which to develop FLT3 mutants-selective inhibitors for AML treatment.
Collapse
Affiliation(s)
- Deheng Sun
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science & Technology , Shanghai 200237, China
| | - Yu Yang
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science & Technology , Shanghai 200237, China
| | - Jiankun Lyu
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science & Technology , Shanghai 200237, China
| | - Wei Zhou
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science & Technology , Shanghai 200237, China
| | - Wenlin Song
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science & Technology , Shanghai 200237, China
| | - Zhenjiang Zhao
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science & Technology , Shanghai 200237, China
| | - Zhuo Chen
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science & Technology , Shanghai 200237, China
| | - Yufang Xu
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science & Technology , Shanghai 200237, China
| | - Honglin Li
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science & Technology , Shanghai 200237, China
| |
Collapse
|
37
|
Yang W, Ye S, Schmidt Y, Stamos D, Yu JQ. Ligand-Promoted C(sp(3) )-H Olefination en Route to Multi-functionalized Pyrazoles. Chemistry 2016; 22:7059-62. [PMID: 26991450 PMCID: PMC4944759 DOI: 10.1002/chem.201600704] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2016] [Indexed: 12/29/2022]
Abstract
A Pd-catalyzed/N-heterocycle-directed C(sp(3) )-H olefination has been developed. The monoprotected amino acid ligand (MPAA) is found to significantly promote Pd-catalyzed C(sp(3) )-H olefination for the first time. Cu(OAc)2 instead of Ag(+) salts are used as the terminal oxidant. This reaction provides a useful method for the synthesis of alkylated pyrazoles.
Collapse
Affiliation(s)
- Weibo Yang
- Department of Chemistry, The Scripps Research Institute (TSRI), 10550 North Torrey Pines Road, La Jolla, CA, 92037, USA
| | - Shengqing Ye
- Department of Chemistry, The Scripps Research Institute (TSRI), 10550 North Torrey Pines Road, La Jolla, CA, 92037, USA
| | - Yvonne Schmidt
- Medicinal Chemistry, Vertex Pharmaceuticals, 11010 Torreyana Rd., San Diego, CA, 92121, USA
| | - Dean Stamos
- Medicinal Chemistry, Vertex Pharmaceuticals, 11010 Torreyana Rd., San Diego, CA, 92121, USA
| | - Jin-Quan Yu
- Department of Chemistry, The Scripps Research Institute (TSRI), 10550 North Torrey Pines Road, La Jolla, CA, 92037, USA.
| |
Collapse
|
38
|
Hennessy EJ, Chuaqui C, Ashton S, Colclough N, Cross DAE, Debreczeni JÉ, Eberlein C, Gingipalli L, Klinowska TCM, Orme JP, Sha L, Wu X. Utilization of Structure-Based Design to Identify Novel, Irreversible Inhibitors of EGFR Harboring the T790M Mutation. ACS Med Chem Lett 2016; 7:514-9. [PMID: 27190603 DOI: 10.1021/acsmedchemlett.6b00058] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2016] [Accepted: 03/21/2016] [Indexed: 12/16/2022] Open
Abstract
A novel series of covalent inhibitors of EGFR (epidermal growth factor receptor) kinase was discovered through a combination of subset screening and structure-based design. These compounds preferentially inhibit mutant forms of EGFR (activating mutant and T790M mutant) over wild-type EGFR in cellular assays measuring EGFR autophosphorylation and proliferation, suggesting an improved therapeutic index in non-small cell lung cancer patients would be achievable relative to established EGFR inhibitors. We describe our design approaches, resulting in the identification of the lead compound 5, and our efforts to develop an understanding of the structure-activity relationships within this series. In addition, strategies to overcome challenges around metabolic stability and aqueous solubility are discussed. Despite limitations in its physical properties, 5 is orally bioavailable in mice and demonstrates pronounced antitumor activity in in vivo models of mutant EGFR-driven cancers.
Collapse
Affiliation(s)
- Edward J. Hennessy
- Oncology iMed, Innovative Medicines & Early Development, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States
| | - Claudio Chuaqui
- Oncology iMed, Innovative Medicines & Early Development, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States
| | - Susan Ashton
- Oncology iMed & Discovery Sciences, Innovative Medicines & Early Development, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Nicola Colclough
- Oncology iMed & Discovery Sciences, Innovative Medicines & Early Development, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Darren A. E. Cross
- Oncology iMed & Discovery Sciences, Innovative Medicines & Early Development, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Judit É. Debreczeni
- Oncology iMed & Discovery Sciences, Innovative Medicines & Early Development, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Cath Eberlein
- Oncology iMed & Discovery Sciences, Innovative Medicines & Early Development, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Lakshmaiah Gingipalli
- Oncology iMed, Innovative Medicines & Early Development, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States
| | - Teresa C. M. Klinowska
- Oncology iMed & Discovery Sciences, Innovative Medicines & Early Development, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Jonathan P. Orme
- Oncology iMed & Discovery Sciences, Innovative Medicines & Early Development, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
| | - Li Sha
- Oncology iMed, Innovative Medicines & Early Development, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States
| | - Xiaoyun Wu
- Oncology iMed, Innovative Medicines & Early Development, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States
| |
Collapse
|
39
|
Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR. Future Med Chem 2016; 8:853-78. [DOI: 10.4155/fmc-2016-0019] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Deregulation of EGFR is involved in the development of many cancers. The inhibition of EGFR kinase activity has been clinically validated as a promising approach for the treatment of non-small-cell lung cancer (NSCLC). However, all NSCLC patients who initially benefited from first-generation EGFR inhibitors eventually develop drug resistance. A point mutation at the gatekeeper position, T790M in EGFR kinase domain accounts for more than 50% of acquired resistance. Therefore, second- and third-generation EGFR inhibitors have been developed to overcome the resistance conferred by the gatekeeper mutation. This review has highlighted recent advances in overcoming acquired resistance for the development of each generation of EGFR inhibitors along with their potential issues, and urgent quest for the development of new generation of EGFR inhibitors.
Collapse
|
40
|
Yu H, Li Y, Ge Y, Song Z, Wang C, Huang S, Jin Y, Han X, Zhen Y, Liu K, Zhou Y, Ma X. Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines. Eur J Med Chem 2016; 110:195-203. [DOI: 10.1016/j.ejmech.2016.01.045] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2015] [Revised: 01/20/2016] [Accepted: 01/22/2016] [Indexed: 12/20/2022]
|
41
|
Song Z, Ge Y, Wang C, Huang S, Shu X, Liu K, Zhou Y, Ma X. Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer. J Med Chem 2016; 59:6580-94. [PMID: 26882288 DOI: 10.1021/acs.jmedchem.5b00840] [Citation(s) in RCA: 72] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Because of the development of drug-resistance mutations, particularly the "gatekeeper" threonine(790)-to-methionine(790) (T790M) mutation in the ATP-binding pocket of the epidermal growth factor receptor (EGFR), the current generation of EGFR tyrosine kinase inhibitors lost their clinical efficacy. Recently, a large number of small-molecule inhibitors with striking inhibitory potency against EGFR mutants with the T790M change have been identified. In particular, the inhibitors rociletinib and osimertinib, which can selectively target both sensitizing mutations and the T790M resistance while sparing the wild-type (WT) form of the receptor, have been designated as breakthrough therapies in the treatment of mutant non-small-cell lung cancer (NSCLC) by the U.S. FDA in 2014. We hope that this review on the small-molecule EGFR T790M inhibitors, along with their discovery strategies, will assist in the design of future T790M-containing EGFR inhibitors with high levels of selectivity over WT EGFR, broad kinase selectivity, and desirable physicochemical properties.
Collapse
Affiliation(s)
- Zhendong Song
- College of Pharmacy, Dalian Medical University , Dalian 116044, P. R. China
| | - Yang Ge
- College of Pharmacy, Dalian Medical University , Dalian 116044, P. R. China
| | - Changyuan Wang
- College of Pharmacy, Dalian Medical University , Dalian 116044, P. R. China
| | - Shanshan Huang
- College of Pharmacy, Dalian Medical University , Dalian 116044, P. R. China
| | - Xiaohong Shu
- College of Pharmacy, Dalian Medical University , Dalian 116044, P. R. China
| | - Kexin Liu
- College of Pharmacy, Dalian Medical University , Dalian 116044, P. R. China
| | - Youwen Zhou
- Department of Dermatology and Skin Science, University of British Columbia , Vancouver, BC, V5Z 4E8, Canada
| | - Xiaodong Ma
- College of Pharmacy, Dalian Medical University , Dalian 116044, P. R. China
| |
Collapse
|
42
|
Cheng H, Nair SK, Murray BW, Almaden C, Bailey S, Baxi S, Behenna D, Cho-Schultz S, Dalvie D, Dinh DM, Edwards MP, Feng JL, Ferre RA, Gajiwala KS, Hemkens MD, Jackson-Fisher A, Jalaie M, Johnson TO, Kania RS, Kephart S, Lafontaine J, Lunney B, Liu KKC, Liu Z, Matthews J, Nagata A, Niessen S, Ornelas MA, Orr STM, Pairish M, Planken S, Ren S, Richter D, Ryan K, Sach N, Shen H, Smeal T, Solowiej J, Sutton S, Tran K, Tseng E, Vernier W, Walls M, Wang S, Weinrich SL, Xin S, Xu H, Yin MJ, Zientek M, Zhou R, Kath JC. Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants. J Med Chem 2016; 59:2005-24. [PMID: 26756222 DOI: 10.1021/acs.jmedchem.5b01633] [Citation(s) in RCA: 67] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
First generation EGFR TKIs (gefitinib, erlotinib) provide significant clinical benefit for NSCLC cancer patients with oncogenic EGFR mutations. Ultimately, these patients' disease progresses, often driven by a second-site mutation in the EGFR kinase domain (T790M). Another liability of the first generation drugs is severe adverse events driven by inhibition of WT EGFR. As such, our goal was to develop a highly potent irreversible inhibitor with the largest selectivity ratio between the drug-resistant double mutants (L858R/T790M, Del/T790M) and WT EGFR. A unique approach to develop covalent inhibitors, optimization of reversible binding affinity, served as a cornerstone of this effort. PF-06459988 was discovered as a novel, third generation irreversible inhibitor, which demonstrates (i) high potency and specificity to the T790M-containing double mutant EGFRs, (ii) minimal intrinsic chemical reactivity of the electrophilic warhead, (iii) greatly reduced proteome reactivity relative to earlier irreversible EGFR inhibitors, and (iv) minimal activity against WT EGFR.
Collapse
Affiliation(s)
- Hengmiao Cheng
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Sajiv K Nair
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Brion W Murray
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Chau Almaden
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Simon Bailey
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Sangita Baxi
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Doug Behenna
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Sujin Cho-Schultz
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Deepak Dalvie
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Dac M Dinh
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Martin P Edwards
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Jun Li Feng
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Rose Ann Ferre
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Ketan S Gajiwala
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Michelle D Hemkens
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Amy Jackson-Fisher
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Mehran Jalaie
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Ted O Johnson
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Robert S Kania
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Susan Kephart
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Jennifer Lafontaine
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Beth Lunney
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Kevin K-C Liu
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Zhengyu Liu
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Jean Matthews
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Asako Nagata
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Sherry Niessen
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Martha A Ornelas
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Suvi T M Orr
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Mason Pairish
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Simon Planken
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Shijian Ren
- Wuxi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China
| | - Daniel Richter
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Kevin Ryan
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Neal Sach
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Hong Shen
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Tod Smeal
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Jim Solowiej
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Scott Sutton
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Khanh Tran
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Elaine Tseng
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - William Vernier
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Marlena Walls
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Shuiwang Wang
- Wuxi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China
| | - Scott L Weinrich
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Shuibo Xin
- Wuxi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China
| | - Haiwei Xu
- Wuxi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China
| | - Min-Jean Yin
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Michael Zientek
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - Ru Zhou
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| | - John C Kath
- La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States
| |
Collapse
|
43
|
Yue L, Du J, Ye F, Chen Z, Li L, Lian F, Zhang B, Zhang Y, Jiang H, Chen K, Li Y, Zhou B, Zhang N, Yang Y, Luo C. Identification of novel small-molecule inhibitors targeting menin–MLL interaction, repurposing the antidiarrheal loperamide. Org Biomol Chem 2016; 14:8503-19. [DOI: 10.1039/c6ob01248e] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Scaffold hopping combines with biochemical studies and medicinal chemistry optimizations, leading to potent inhibitors of the menin–MLL interaction.
Collapse
|
44
|
Chang K, Shi Y, Chen J, He Z, Xu Z, Zhao Z, Zhu W, Li H, Xu Y, Li B, Qian X. The discovery of new plant activators and scaffolds with potential induced systemic resistance: from jasmonic acid to pyrrolidone. MEDCHEMCOMM 2016. [DOI: 10.1039/c6md00261g] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A series of novel plant activators possessing a pyrrolidone scaffold was developed with the help of SHAFTS.
Collapse
|
45
|
Qin M, Wang T, Xu B, Ma Z, Jiang N, Xie H, Gong P, Zhao Y. Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant. Eur J Med Chem 2015; 104:115-26. [DOI: 10.1016/j.ejmech.2015.09.031] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2015] [Revised: 09/17/2015] [Accepted: 09/24/2015] [Indexed: 10/23/2022]
|
46
|
Wurz RP, Pettus LH, Ashton K, Brown J, Chen JJ, Herberich B, Hong FT, Hu-Harrington E, Nguyen T, St. Jean DJ, Tadesse S, Bauer D, Kubryk M, Zhan J, Cooke K, Mitchell P, Andrews KL, Hsieh F, Hickman D, Kalyanaraman N, Wu T, Reid DL, Lobenhofer EK, Andrews DA, Everds N, Guzman R, Parsons AT, Hedley SJ, Tedrow J, Thiel OR, Potter M, Radinsky R, Beltran PJ, Tasker AS. Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors. ACS Med Chem Lett 2015; 6:987-92. [PMID: 26396685 DOI: 10.1021/acsmedchemlett.5b00193] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2015] [Accepted: 07/27/2015] [Indexed: 01/26/2023] Open
Abstract
In nonsmall cell lung cancer (NSCLC), the threonine(790)-methionine(790) (T790M) point mutation of EGFR kinase is one of the leading causes of acquired resistance to the first generation tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. Herein, we describe the optimization of a series of 7-oxopyrido[2,3-d]pyrimidinyl-derived irreversible inhibitors of EGFR kinase. This led to the discovery of compound 24 which potently inhibits gefitinib-resistant EGFR(L858R,T790M) with 100-fold selectivity over wild-type EGFR. Compound 24 displays strong antiproliferative activity against the H1975 nonsmall cell lung cancer cell line, the first line mutant HCC827 cell line, and promising antitumor activity in an EGFR(L858R,T790M) driven H1975 xenograft model sparing the side effects associated with the inhibition of wild-type EGFR.
Collapse
Affiliation(s)
- Ryan P. Wurz
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Liping H. Pettus
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Kate Ashton
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - James Brown
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Jian Jeffrey Chen
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Brad Herberich
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Fang-Tsao Hong
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Essa Hu-Harrington
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Tom Nguyen
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - David J. St. Jean
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Seifu Tadesse
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - David Bauer
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Michele Kubryk
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Jinghui Zhan
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Keegan Cooke
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Petia Mitchell
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Kristin L. Andrews
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Faye Hsieh
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Dean Hickman
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Nataraj Kalyanaraman
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Tian Wu
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Darren L. Reid
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Edward K. Lobenhofer
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Dina A. Andrews
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Nancy Everds
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Roberto Guzman
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Andrew T. Parsons
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Simon J. Hedley
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Jason Tedrow
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Oliver R. Thiel
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Matthew Potter
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Robert Radinsky
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Pedro J. Beltran
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Andrew S. Tasker
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| |
Collapse
|
47
|
Zhang Y, Zhang K, Zhao M, Zhang L, Qin M, Guo S, Zhao Y, Gong P. Discovery of a novel class anti-proliferative agents and potential inhibitors of EGFR tyrosine kinases based on 4-anilinotetrahydropyrido[4,3-d]pyrimidine scaffold: Design, synthesis and biological evaluations. Bioorg Med Chem 2015; 23:4591-4607. [DOI: 10.1016/j.bmc.2015.05.059] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2015] [Revised: 05/29/2015] [Accepted: 05/30/2015] [Indexed: 10/23/2022]
|
48
|
Liu W, Ning JF, Meng QW, Hu J, Zhao YB, Liu C, Cai L. Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent. DRUG DESIGN DEVELOPMENT AND THERAPY 2015; 9:3837-51. [PMID: 26229444 PMCID: PMC4517520 DOI: 10.2147/dddt.s85357] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The epidermal growth factor receptor (EGFR) family has been validated as a successful antitumor drug target for decades. Known EGFR inhibitors were exposed to distinct drug resistance against the various EGFR mutants within non-small-cell lung cancer (NSCLC), particularly the T790M mutation. Although so far a number of studies have been reported on the development of third-generation EGFR inhibitors for overcoming the resistance issue, the design procedure largely depends on the intuition of medicinal chemists. Here we retrospectively make a detailed analysis of the 42 EGFR family protein crystal complexes deposited in the Protein Data Bank (PDB). Based on the analysis of inhibitor binding modes in the kinase catalytic cleft, we identified a potent EGFR inhibitor (compound A-10) against drug-resistant EGFR through fragment-based drug design. This compound showed at least 30-fold more potency against EGFR T790M than the two control molecules erlotinib and gefitinib in vitro. Moreover, it could exhibit potent HER2 inhibitory activities as well as tumor growth inhibitory activity. Molecular docking studies revealed a structural basis for the increased potency and mutant selectivity of this compound. Compound A-10 may be selected as a promising candidate in further preclinical studies. In addition, our findings could provide a powerful strategy to identify novel selective kinase inhibitors on the basis of detailed kinase–ligand interaction space in the PDB.
Collapse
Affiliation(s)
- Wei Liu
- The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China
| | - Jin-Feng Ning
- The Thoracic Surgery Department, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China
| | - Qing-Wei Meng
- The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China
| | - Jing Hu
- The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China
| | - Yan-Bin Zhao
- The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China
| | - Chao Liu
- General Surgery Department, Mudanjiang Guanliju Central Hospital, Mishan, Heilongjiang Province, People's Republic of China
| | - Li Cai
- The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China
| |
Collapse
|
49
|
Basu D, Richters A, Rauh D. Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR. Bioorg Med Chem 2015; 23:2767-80. [PMID: 25975640 DOI: 10.1016/j.bmc.2015.04.038] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2015] [Revised: 04/12/2015] [Accepted: 04/14/2015] [Indexed: 01/04/2023]
Abstract
The clinical success of covalent kinase inhibitors in the treatment of EGFR-dependent non-small cell lung cancer (NSCLC) has rejuvenated the appreciation of reactive small molecules. Acquired drug resistance against first-line EGFR inhibitors remains the major bottleneck in NSCLC and is currently addressed by the application of fine-tuned covalent drugs. Here we report the design, synthesis and biochemical evaluation of a novel class of EGFR inhibitors with a covalent yet reversible warhead. A series of WZ4002 analogs, derived from anilinopyrimidine and 3-substituted-2-cyanoacrylamide scaffolds, exhibit strong and selective inhibitory activity against clinically relevant EGFR(L858R) and EGFR(L858R/T790M).
Collapse
Affiliation(s)
- Debjit Basu
- Department of Chemistry and Chemical Biology, Technische Universität Dortmund, Otto-Hahn-Straße 6, 44227 Dortmund, Germany
| | - André Richters
- Department of Chemistry and Chemical Biology, Technische Universität Dortmund, Otto-Hahn-Straße 6, 44227 Dortmund, Germany
| | - Daniel Rauh
- Department of Chemistry and Chemical Biology, Technische Universität Dortmund, Otto-Hahn-Straße 6, 44227 Dortmund, Germany.
| |
Collapse
|
50
|
Xu T, Peng T, Ren X, Zhang L, Yu L, Luo J, Zhang Z, Tu Z, Tong L, Huang Z, Lu X, Geng M, Xie H, Ding J, Ding K. C5-substituted pyrido[2,3-d]pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFRT790M mutant. MEDCHEMCOMM 2015. [DOI: 10.1039/c5md00208g] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
C5-substituted pyrido[2,3-d]pyrimidin-7-ones were discovered as highly potent and specific inhibitors targeting the clinical resistance-related EGFRL858R/T790M mutant.
Collapse
|